Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
31
datasets available to search
ShareScore release 0.9.0
Dataset results
31 results for “D-serine”
Data for: Excitatory and inhibitory D-serine binding to the NMDA receptor
<p>N-methyl-D-aspartate receptors (NMDARs) uniquely require binding of two different neurotransmitter agonists for synaptic transmission. D-serine and glycine bind to one subunit, GluN1, while glutamate binds to the other, GluN2. These agonists bind to the receptor's bi-lobed ligand-binding domains (LBDs), which close around the agonist during receptor activation. To better understand the unexplored mechanisms by which D-serine contributes to receptor activation, we performed multi-microsecond molecular dynamics simulations of the GluN1/GluN2A LBD dimer with free D-serine and glutamate agonists. Surprisingly, we observed D-serine binding to both GluN1 and GluN2A LBDs, suggesting that D-serine competes with glutamate for binding to GluN2A. This mechanism is confirmed by our electrophysiology experiments, which show that D-serine is indeed inhibitory at high concentrations. Although free energy calculations indicate that D-serine stabilizes the closed GluN2A LBD, its inhibitory behavior suggests that it either does not remain bound long enough or does not generate sufficient force for ion channel gating. We developed a workflow using pathway similarity analysis to identify groups of residues working together to promote binding. These conformation-dependent pathways were not significantly impacted by the presence of N-linked glycans, which act primarily by interacting with the LBD bottom lobe to stabilize the closed LBD.</p>
D-serine and Cognitive Remediation in Schizophrenia
ClinicalTrials.gov study NCT02156908. IPD Sharing: Not stated. Countries: 1. Publications: 1.
D-serine for the Schizophrenia Prodrome
ClinicalTrials.gov study NCT00826202. IPD Sharing: Not stated. Countries: 1. Publications: 1.
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
ClinicalTrials.gov study NCT00237809. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Safety and Effectiveness of D-serine in Schizophrenia
ClinicalTrials.gov study NCT00322023. IPD Sharing: Not stated. Countries: 1. Publications: 1.
D-serine Augmentation of Neuroplasticity
ClinicalTrials.gov study NCT03711500. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Data for: Excitatory and inhibitory D-serine binding to the NMDA receptor
Open the record for dataset details and reuse information.
Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia
ClinicalTrials.gov study NCT00138775. IPD Sharing: Not stated. Countries: 1. Publications: 1.
D-serine Adjuvant Treatment for Parkinson's Disease
ClinicalTrials.gov study NCT00215904. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans
ClinicalTrials.gov study NCT02051426. IPD Sharing: Not stated. Countries: 0. Publications: 1.
D-serine for Posttraumatic Stress Disorder Treatment
ClinicalTrials.gov study NCT00215878. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pharmacologic Augmentation of TMS for Depression With D-serine
ClinicalTrials.gov study NCT06876129. IPD Sharing: NO. Countries: 1. Publications: 3.
D-serine Supplementation for Depression
ClinicalTrials.gov study NCT04721249. IPD Sharing: NO. Countries: 1. Publications: 1.
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
ClinicalTrials.gov study NCT00491569. IPD Sharing: Not stated. Countries: 1. Publications: 2.
D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
ClinicalTrials.gov study NCT00237848. IPD Sharing: Not stated. Countries: 1. Publications: 3.
D-Serine for Cocaine Dependence Pilot
ClinicalTrials.gov study NCT01715051. IPD Sharing: Not stated. Countries: 1. Publications: 3.
D-Serine activates glycolysis via mTOR pathway in kidney remodeling and suppresses onset of diabetes
GEO Series GSE155475. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
D-serine in Schizophrenia
ClinicalTrials.gov study NCT03702933. IPD Sharing: Not stated. Countries: 1. Publications: 0.
D-serine Monotherapy for Schizophrenia
ClinicalTrials.gov study NCT00816894. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
ClinicalTrials.gov study NCT04140773. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.